platoseedplatoseed
Reprogramming Immunity for Target-Specific Medicines
Granza Bio is developing programmable therapeutics for the immune system. Our platform is built on the foundational discovery of immune “superkiller” attack particles — the natural ammunition used by cytotoxic immune cells to deliver potent, localized killing. By re-arming exhausted immune cells with newly programmed ammunition, Granza restores and enhances immune function. This approach enables a new class of treatments with the potential to transform diseases ranging from cancer to autoimmunity.
Granza Bio focuses on reprogramming immunity to create target-specific medicines, leveraging autonomous immune attack particles discovered in cytotoxic immune cells to combat cancer, autoimmune diseases, and infections.
The company utilizes a platform built around autonomous immune attack particles derived from cytotoxic immune cells, aiming to deploy these particles as targeted therapeutic agents to fight diseases such as cancers, autoimmunity, and infections.
Who it’s for: Biotech/healthcare researchers and developers working on immunotherapies and targeted medicines
research-backed concept with academic affiliation; early-stage mention (no funding/hiring details provided)
Ashwin completed his PhD (DPhil) in Oncology at the University of Oxford. After completing his PhD, he began working as a Cancer Research UK post-doctoral researcher at Oxford University and also at the Institute of Cancer Research (ICR), London. He also brings experience setting up oncology clinical trials and working in oncology start-ups.
Granza Bio, DPhil (PhD) in Interdisciplinary Bioscience - University of Oxford
We engineer "attack particles" that selectively target and kill cancer cells, eliminating unwanted side effects and toxicity.
Granza Bio develops personalised cancer therapies using engineered attack particles that selectively kill cancer cells while sparing healthy tissue, aiming to cross the blood-brain barrier and enable a platform approach for multiple diseases. The launch introduces the team, the problem of treatment toxicity, and the solution’s core value of targeted cancer killing with minimal side effects.
From the original launch (Feb 2024) — may be outdated.
Formerly “Zyme Therapeutics” · why startups rename →
Genetically engineered viruses that teach your immune system to kill…
We teach your immune system to attack and cure cancer
